Fineline Cube

Follow:
14437 Articles
Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment
CompanyMedical Device

Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment

JW Therapeutics Enters Licensing Pact with Juno Therapeutics for sLVV Process
CompanyDeals

JW Therapeutics Enters Licensing Pact with Juno Therapeutics for sLVV Process

iMBIORAY Gains NMPA Approval for Phase IITrial of IBR854 in Advanced RCC
Drug

iMBIORAY Gains NMPA Approval for Phase IITrial of IBR854 in Advanced RCC

Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment
CompanyDrug

Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment

Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines
CompanyDeals

Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines

Akeso's Ivonescimab Shows Strong Results in Phase III Trial for Sq-NSCLC
CompanyDrug

Akeso’s Ivonescimab Shows Strong Results in Phase III Trial for Sq-NSCLC

BMS Secures NMPA Approval for Opdivo in Resectable NSCLC Neoadjuvant Therapy
CompanyDrug

BMS Secures NMPA Approval for Opdivo in Resectable NSCLC Neoadjuvant Therapy

AstraZeneca's Ultomiris Approved in China for Generalized Myasthenia Gravis
CompanyDrug

AstraZeneca’s Ultomiris Approved in China for Generalized Myasthenia Gravis

Zai Lab's Augtyro NDA Accepted by China's NMPA for NTRK Fusion Solid Tumors
CompanyDrug

Zai Lab’s Augtyro NDA Accepted by China’s NMPA for NTRK Fusion Solid Tumors

Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder
CompanyDrug

Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder

Dizal Pharma Secures RMB 1.796 Billion Private Placement to Advance R&D and Facilities
CompanyDeals

Dizal Pharma Secures RMB 1.796 Billion Private Placement to Advance R&D and Facilities

Bio-Thera Solutions Gains NMPA Clinical Approval for BAT7111 in Advanced Solid Tumors
CompanyDrug

Bio-Thera Solutions Gains NMPA Clinical Approval for BAT7111 in Advanced Solid Tumors